L&T Technology Services Unveils CoE to Offer Suite of Automotive Solutions on AWS
9.3.2023 10:30:00 EET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced a new Centre of Excellence (CoE) in Mysore (Karnataka, India) that leverages the power of the cloud with Amazon Web Services (AWS). The CoE will allow LTTS to transition its suite of cutting-edge technologies focused on the future of mobility and reduce time-to-market for end customers. By leveraging AWS infrastructure, LTTS will provide an opportunity to use AWS to support the automotive domain.
With its rich engineering domain expertise in Electric, Autonomous, and Connected Vehicles (EACV), LTTS has been helping OEMs to develop next-generation Vehicles and Aircraft that have tailored solutions focused on safety and security. The new CoE will leverage LTTS' cross-disciplinary skillsets covering embedded, mechanical, and digital facets of engineering.
LTTS has been actively working with global technology leaders like AWS to bring digital engineering solutions to end customers on the cloud. AnnotAI , Connected Cars , and SafeX are some of the LTTS solutions that will be deployed in AWS Marketplace to optimize R&D innovation on the cloud to create enterprise-leading technology solutions.
LTTS’ industry leading mobility solutions are helping OEMs to build innovative next-generation vehicles to meet and exceed the standards for transport safety, security, and emission regulations. LTTS’ AnnotAI, Connected Cars and SafeX solutions have already been deployed for leading global Automotive OEMs and Tier-1 customers, helping them reap significant faster time-to-market benefits. As part of the CoE, AWS software-defined vehicle and AWS IoT FleetWise will be used alongside LTTS’ digital offerings to collect and transfer the vehicle data to the cloud in near real time.
- AnnotAI : For the purpose of developing and testing a self-driving artificial intelligence (AI), a large amount of data is required, along with more engineering and data labeling services. LTTS’ intelligent data annotation platform AnnotAI provides smart labelling to media assets such as text, image, video, and LiDAR, thus empowering global vehicle manufacturers in their drive towards Level 5 autonomy (full driving automation or where the dynamic driving task is eliminated).
- Connected Car : LTTS’ Connected Car technologies offers automotive clients with state-of-the-art driver assistance systems, cloud services and connectivity modules which support in development of V2X platform definition, while implementing secured gateways and avoiding malicious attacks.
- SafeX : The automotive industry faces unique challenges when it comes to developing state-of-the-art software. SafeX DevOps and CI/CD automation allows automotive manufacturers to accelerate their releases while ensuring security and mitigating the risk of failed or recalled software releases.
LTTS’ suite of cutting-edge technologies has resulted in proven benefits for global customers.
A Spokesperson from BMW Group said, “The AnnotAI platform from LTTS, by enabling state-of-the-art image, video, and LiDAR data annotation capabilities on AWS, is driving a robust and integrated validation framework for BMW Group and helping the global leader in luxury vehicles engineer innovative and sustainable vehicles for the future.”
Amit Chadha, CEO and Managing Director, L&T Technology Services said, “Electric, Autonomous and Connected Vehicle (EACV) is the first of our six big bets that are helping global automotive players accelerate their technological development journey towards an autonomous and sustainable future built on the highest considerations of security and safety. By working with AWS, LTTS can help global automotive organizations realize the full potential of its high-performance and scalable technologies built on an agile AWS cloud infrastructure.”
Puneet Chandok, President of Commercial Business, AWS India & South Asia (Amazon Web Services India Pvt. Ltd.) said, “The digital transformation in the automotive industry is accelerating, in many cases thanks to innovative solutions coming from our AWS partners. LTTS’ digital engineering offerings will help our joint customers realize the benefits of moving to the cloud, such as reduced time to market, increased business value and accelerated pace of digital innovation. With the launch of the new Centre of Excellence in India, LTTS will enable customers and original equipment manufacturers (OEM) with a broader range of services and solutions to support their digital transformation journeys.”
Akshat Vaid, Partner at Everest Group said, “For some years now, innovation in mobility has been software and technology centric with themes such as hybrid and electric, autonomous driving, connected experiences, and shared mobility, continuing to be top ER&D spend segments. Cloud and edge computing are naturally at the front and centre in this new era of automotive engineering. Alliances between cloud leaders and engineering service providers will go a long way in helping OEMs in driving best engineering outcomes and in the process creating new possibilities for their end-consumers.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 21,600 employees spread across 22 global design centers, 28 global sales offices and 91 innovation labs as of December 31, 2022. For more information, please visit www.ltts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005905/en/
Contact information
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.basu@ltts.com
T: +91-80-67675707
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom